Bellicum Pharmaceuticals Inc

Bellicum Pharmaceuticals — Investor Presentation (January 2020)

29 slides from Bellicum Pharmaceuticals's investor presentation, Jan 15, 2020

  1. Slide 1: Investor Presentation: Building a powerful new future in cellular IO

    Investor Presentation Building a powerful new future in cellular IO January 2020

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation contains estimates, projections and other forward-looking statements, concerning, among other things: our research and development activities relating to our GoCAR™ (incorporating “iMC”), GoCAR-T ® CaspaCIDe® (“iC9”), and related technologies; our product

  3. Slide 3: Investment Summary

    Investment Summary Building a next generation cell therapy pipeline around the GoCAR platform GoCAR Platform Differentiated co-activation domain (MyD88/CD40) and switch technology drive greater proliferation, persistence, power, and performance BPX-601 BPX-603 GoCAR-NK Program • Autologous GoCAR-T t

  4. Slide 4: Technology Overview

    Technology Overview ‘=> Bellicum 4

  5. Slide 5: GoCAR: Differentiated Technology Platform

    GoCAR: Differentiated Technology Platform Current Generation CAR Technology Next Generation GoCAR Technology 5

  6. Slide 6: GoCAR: Driving the Future of Cellular IO

    GoCAR: Driving the Future of Cellular IO Persistence Proliferation Enhances effector cell Boosts effector cell functional persistence by proliferation and extends resisting exhaustion and survival of these inhibitory signals from activated cells, leading to the tumor environment more durable respons

  7. Slide 7: GoCAR Proliferation: Superior Expansion and Resistance to T Cell Exhaustion

    GoCAR Proliferation: Superior Expansion and Resistance to T Cell Exhaustion iMC activation limits T cell dysfunction in repeat tumor stimulation exhaustion assay T cell T cell expansion IL-2 production HER2+ tumor 100 100000 cells BPX-603 + Rim 10000 BPX-603 + Rim NT NT 1000 Repeat HER2.z HER2.z tum

  8. Slide 8: GoCAR Persistence: Resistance to Immune Suppressive TME

    GoCAR Persistence: Resistance to Immune Suppressive TME iMC overrides common inhibitory molecules in the tumor microenvironment Inhibitory TME PD-L1 TGF-b 140 35 BPX-601 + Rim 120 30 BPX-601 + Rim M2 M 100 25 PGE2 MDSC 80 PSCA 20 PSCA PSCA + PD-L1 PSCA + TGF-b PD-L1 60 15 T T index proliferation T

  9. Slide 9: Expanding Proprietary Development Pipeline

    Expanding Proprietary Development Pipeline CLINICAL PROOF OF DISCOVERY IND ENABLING STATUS PRODUCT CANDIDATE CONCEPT Wholly owned proprietary development programs: • Cohort 5B new translational data BPX-601 at ASCO GI in Jan 2020 GoCAR-T Pancreatic Cancer, Phase 1/2 PSCA • Cohort 5C repeat Rim clini

  10. Slide 10: BPX-601 PSCA Autologous GoCAR-T

    BPX-601 PSCA Autologous GoCAR-T 10

  11. Slide 11: BPX-601 GoCAR-T Targets Solid Tumors Expressing PSCA

    BPX-601 GoCAR-T Targets Solid Tumors Expressing PSCA Product Profile Summary Unmet Need ▪ Attractive first-in-class solid tumor CAR-T opportunity High unmet need in solid tumors expressing prostate stem cell antigen (PSCA) ▪ First-in-human experience with iMC Annual Annual % Expressing ▪ Updated Pha

  12. Slide 12: BPX-601: Phase 1/2 Trial Enrolling Cohort 5C

    BPX-601: Phase 1 Trial Enrolling Cohort 5C BP-012 trial in relapsed/refractory pancreatic cancer Dose Standard Lead-in Repeat Rimiducid Lead-In & Dose Escalation Escalation Conditioning (Cohort 0) (Cohort 5C) (Cohorts 3, 4, 5A) (Cohort 5B) Conservatively designed to evaluate safety • Lead-in cohort

  13. Slide 13: BPX-601: No Dose Limiting Toxicities Observed

    BPX-601: No Dose Limiting Toxicities Observed Data presented at ASCO 2019 ▪ No dose limiting toxicities observed Cohort 0 Cohort 3 Cohort 4 Cohort 5A Cohort 5B All Patients Patients, n (%) n = 3 n = 3 n = 3 n = 4 n = 5 N = 18 ▪ Adverse Events (AEs) were generally Any AE 3 (100) 3 (100) 3 (100) 4 (10

  14. Slide 14: BPX-601: iMC-Driven T Cell Expansion & Persistence

    BPX-601: iMC-Driven T Cell Expansion & Persistence Flu/Cy Lymphodepletion results in Increased BPX-601 cell expansion and persistence 1 0 5 R im ▪ Peak expansion 4.9-fold higher ) A in Flu/Cy cohort vs Cy alone N 4 * D 1 0 T cohorts g - R g  A 3 / 1 0 C s ▪ Persistence improves with: o e i G p 2 o

  15. Slide 15: BPX-601: Evidence of Anti-tumor Activity

    BPX-601: Evidence of Anti-tumor Activity ▪ 8 (62%) of 13 evaluable patients treated with BPX- 601 and single-dose rim achieved stable disease; 3 had tumor shrinkage of 10- 24% ▪ With 9.1 weeks median follow-up (range: 2.9-30.3), median time to next cancer therapy in patients that received subsequent

  16. Slide 16: BPX-603 HER-2 Autologous GoCAR-T

    BPX-603 HER-2 Autologous GoCAR-T 16

  17. Slide 17: BPX-603 Dual Switch GoCAR-T Targeting HER2

    BPX-603 Dual Switch GoCAR-T Targeting HER2 Product Profile Summary Unmet Need ▪ HER2 is a validated tumor antigen expressed on numerous 1 + 5-year OS Indication Incidence HER2 1 solid tumors with high unmet need (Stage IV) Gastric 28,000 10-30%3 <20% ▪ Historical HER2 CAR-T studies have shown modest

  18. Slide 18: Historical HER2 Studies: Modest Clinical Outcomes

    Historical HER2 Studies: Modest Clinical Outcomes Study Properties Morgan, 2010 Ahmed, 2015 Feng, 2017 Ahmed, 2017 Hegde, 2019 Construct 4D5-28-BB-z FRP5-28-z Her2-BB-z FRP5-28-z FRP5-28-z Indication(s) Metastatic colon Sarcomas CCA and PCa GBM Sarcomas Patient number 1 19 11 17 10 HER2 expression ≥

  19. Slide 19: BPX-603: Compelling Preclinical Evidence

    BPX-603: Compelling Preclinical Evidence Increased CAR-T expansion Increased Efficacy with Higher Affinity Binder iMC activation enhances CAR-T cell proliferation compared to Comparison to lower affinity binder conventional costimulatory domains T cell bioluminescence Tumor growth 10000000 100 Milli

  20. Slide 20: BPX-603 Regulatory Status

    BPX-603 Regulatory Status ▪ IND application on hold pending additional non-clinical data to characterize the potential risk of off-tumor / on-target toxicity ▪ Based on dialogue with FDA, Bellicum believes additional in vitro studies may be sufficient to address FDA’s questions and has initiated the

  21. Slide 21: BCMA OTS GoCAR-NK

    BCMA OTS GoCAR-NK 21

  22. Slide 22: GoCAR-NK Powers Potential of NK Cell Therapies

    GoCAR-NK Powers Potential of NK Cell Therapies NK Cells Have Therapeutic Other NK Cell Features Limit Preclinical Data Support GoCAR-NK Advantages Therapeutic Utility Advantages • Innate ability to kill tumor • Unmodified NK cells • MC improves proliferation and cells through multiple show limited i

  23. Slide 23: iMC Drives NK Cell Proliferation

    iMC Drives NK Cell Proliferation iMC and IL-15 synergize to promote NK cell survival and persistence NK persistence (tumor-free mice) 1.0E+07 ▪ NK cell infusions frequently suffer 1.0E+06 from poor growth and survival NK ▪ iMC activation enhances NK cell 1.0E+05 DS-NK expansion DS-NK + Rim 1.0E+04 D

  24. Slide 24: iMC Increases Innate Cytotoxicity of NK Cells

    iMC Increases Innate Cytotoxicity of NK Cells ▪ CAR-based cell therapies frequently suffer from tumor Monocytic Leukemia (THP1) Pancreatic adenocarcinoma (HPAC) relapse due to loss of the CAR 100 100 antigen’s expression 90 90 80 80 ▪ NK cells possess mechanisms to 70 70 direct innate anti-tumor 60

  25. Slide 25: MC/IL-15 BCMA CAR-NK Cells - Anti-tumor Efficacy

    MC/IL-15 BCMA CAR-NK Cells - Anti-tumor Efficacy CAR-NK persistence with rimiducid stimulation extends past eight weeks + BCMA Tumor only + NK GoCAR/IL15 H929 Tumor growth 1E+09 100000000 10000000 Mock 1000000 NK 100000 NK cell injection cell NK - 10000 MC/IL-15 BCMACAR-NK Tumor Radiance Tumor 1000

  26. Slide 26: BCMA - Attractive Target for OTS GoCAR-NK

    BCMA - Attractive Target for OTS GoCAR-NK ▪ BCMA is a well validated target for autologous CAR-T therapy ▪ High response rates observed in pivotal trial (73.4%1) with emerging questions about durability (mDoR 10.6mo1) ▪ GoCAR-NK has the opportunity to improve durability ▪ GoCAR enhances NK cell pers

  27. Slide 27: Summary

    Summary ‘=> Bellicum 2

  28. Slide 28: Anticipated Key Program Goals & Milestones

    Anticipated Key Program Goals & Milestones Goals & Milestones Timing Presentation of new translational results, cohort 5B Jan 2020 BPX-601 Presentation of interim repeat Rim data, cohort 5C 2H 2020 IND clearance, dependent on resolution of FDA request for additional non- Update 2H 2020 BPX-603 clini

  29. Slide 29: Investment Summary

    Investment Summary Building a next generation cell therapy pipeline around the GoCAR platform GoCAR Platform Differentiated co-activation domain (MyD88/CD40) and switch technology drive greater proliferation, persistence, power, and performance BPX-601 BPX-603 GoCAR-NK Program • Autologous GoCAR-T t

Bellicum Pharmaceuticals — Investor Presentation (January 2020) on 6ix